等待内容更新

艾司洛尔说明书

 

中文别名： 艾司洛尔、艾思洛尔 英文别名： Brevibloc      药品类别： 抗心律失常药

药理药动
	本品为超短效、具有心脏选择性的β1受体阻滞药。经动物实验表明，其β受体阻滞作用为普萘洛尔的1／40，治疗剂量时无内在拟交感活性和明显的膜稳定性。主要阻滞心肌的βl受体，当剂量大于40～100倍时，也阻滞支气管和血管肌肉系统。其电生理特点，主要抑制窦房结和房室结功能，抑制窦房结恢复时间，延长房室结的功能性不应期，相对不应期及文氏周期长度，使房室结传导减慢，PR及HA间期延长，并有提高致室颤阈值的作用。  【药动学】  　　静注本品每分钟400μg／kg，5min内即达到稳态血药浓度，血浆蛋白结合率为55％，表观分布容积为3.43L／kg。本品主要由血液中酯酶催化而使酯基水解失活。在体内分布和消除极快，分布半减期为2min，消除半减期为9min，总体清除率为20L/kg·h，大于心输出量3倍左右。从粪便排出约5％～6％，以原形从尿中排出不足1％。

适 应 症
	适用于手术后心动过速、高血压和急性局部心肌缺血，尤其对因交感张力或儿茶酚胺水平增高引起的室上性快速型心律失常更为有效。对药物或电解质平衡失调和QT间期延长综合征诱发的尖端扭转型室性心动过速等不适用于常规β受体阻滞药者，应用本品不但有效，且可提供其他β受体阻滞药所不具备的安全性。本品具有半减期短、清除率高等优点，因此起效迅速，无蓄积作用，是一种安全快速有效的中止室上性心动过速的药物。

用法用量
	静脉滴注，开始每分钟为50μg/kg，以后每次每分钟增加50μg／kg，直至最大剂量为每分钟300μg/kg为止，每次增加剂量前，应给予1min负荷剂量为500μg/kg。对手术前后出现的心动过速和高血压，应先给予4min负荷剂量，每分钟为500μg/kg，然后维持输注每分钟为300μg/kg。  　　在静脉滴注过程中，应密切注意心率及血压变化。

不良反应
	最常见的不良反应为低血压。

禁忌症
	对明显心动过缓(心率＜ 50次／min)、严重房室传导阻滞、心源性休克、心功能不全患者绝对禁用。对哮喘、阻塞性支气管肺部疾病患者则相对禁用。

药物相互作用
	本品与地高辛合用，可提高地高辛血药浓度；与吗啡合用，可提高艾司洛尔的血药浓度；与华法林合用，可使艾司洛尔血药浓度有轻度提高。

 

Generic Name: esmolol (ES moe lol)
Brand Name: Brevibloc

 

Brevibloc (Esmolol Hydrochloride) is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Brevibloc is also indicated in noncompensatory sinus tachycardia where, in the physician's judgment, the rapid heart rate requires specific intervention. Brevibloc is intended for short-term use.

Brevibloc (Esmolol Hydrochloride) is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician's judgment such specific intervention is considered indicated.

Use of Brevibloc to prevent such events is not recommended.

 

Brevibloc is administered by continuous intravenous infusion with or without a loading dose. Additional loading doses and/or titration of the maintenance infusion (step-wise dosing) may be necessary based on desired ventricular response.

In the absence of loading doses, continuous infusion of a single concentration of esmolol reaches pharmacokinetic and pharmacodynamic steady-state in about 30 minutes.

The effective maintenance dose for continuous and step-wise dosing is 50 to 200 mcg per kg per minute, although doses as low as 25 mcg per kg per minute have been adequate. Dosages greater than 200 mcg per kg per minute provide little added heart rate lowering effect, and the rate of adverse reactions increases.

Maintenance infusions may be continued for up to 48 hours.

In this setting it is not always advisable to slowly titrate to a therapeutic effect. Therefore two dosing options are presented:  immediate control and gradual control.

Immediate Control

Administer 1 mg per kg as a bolus dose over 30 seconds followed by an infusion of 150 mcg per kg per min if necessary.Adjust the infusion rate as required to maintain desired heart rate and blood pressure. Refer to Maximum Recommended Doses below.

Gradual Control

Administer 500 mcg per kg as a bolus dose over 1 minute followed by a maintenance infusion of 50 mcg per kg per min for 4 minutes.Depending on the response obtained, continue dosing as outlined for supraventricular tachycardia. Refer to Maximum Recommended Doses below.

Maximum Recommended Doses

For the treatment of tachycardia, maintenance infusion dosages greater than 200 mcg per kg per min are not recommended; dosages greater than 200 mcg per kg per min provide little additional heart rate-lowering effect, and the rate of adverse reactions increases.For the treatment of hypertension, higher maintenance infusion dosages (250-300 mcg per kg per min) may be required. The safety of doses above 300 mcg per kg per minute has not been studied.

After patients achieve adequate control of the heart rate and a stable clinical status, transition to alternative antiarrhythmic drugs may be accomplished.

When transitioning from Brevibloc to alternative drugs, the physician should carefully consider the labeling instructions of the alternative drug selected and reduce the dosage of Brevibloc as follows:

1.    Thirty minutes following the first dose of the alternative drug, reduce the Brevibloc infusion rate by one-half (50%).

2.    After administration of the second dose of the alternative drug, monitor the patient's response and if satisfactory control is maintained for the first hour, discontinue the Brevibloc infusion.

Brevibloc injection is available in a pre-mixed bag and ready-to-use vial. Brevibloc is not compatible with Sodium Bicarbonate (5%) solution (limited stability) or furosemide (precipitation).

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Premixed Bag

The medication port is to be used solely for withdrawing an initial bolus from the bag.Use aseptic technique when withdrawing the bolus dose.Do not add any additional medications to the bag.

Ready-to-Use Vial

The Ready-to-use Vial may be used to administer a loading dosage by hand-held syringe while the maintenance infusion is being prepared [see How Supplied/Storage and Handling (16.2)].

Compatibility with Commonly Used Intravenous Fluids

Brevibloc was tested for compatibility with ten commonly used intravenous fluids at a final concentration of 10 mg esmolol hydrochloride per mL. Brevibloc was found to be compatible with the following solutions and was stable for at least 24 hours at controlled room temperature or under refrigeration:

Dextrose (5%) Injection, USPDextrose (5%) in Lactated Ringer's InjectionDextrose (5%) in Ringer's InjectionDextrose (5%) and Sodium Chloride (0.45%) Injection, USPDextrose (5%) and Sodium Chloride (0.9%) Injection, USPLactated Ringer's Injection, USPPotassium Chloride (40 mEq/liter) in Dextrose (5%) Injection, USPSodium Chloride (0.45%) Injection, USPSodium Chloride (0.9%) Injection, USP

All Brevibloc dosage forms are iso-osmotic solutions of esmolol hydrochloride in sodium chloride.

Brevibloc (Esmolol Hydrochloride) is contraindicated in patients with:

Severe sinus bradycardia:  May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions (5.2)].Heart block greater than first degree:  Second- or third-degree atrioventricular block may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions (5.2)].Sick sinus syndrome:  May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions (5.2)].Decompensated heart failure:  May worsen heart failure.Cardiogenic shock:  May precipitate further cardiovascular collapse and cause cardiac arrest.IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and Brevibloc in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving Brevibloc and intravenous verapamil.Pulmonary hypertension:  May precipitate cardiorespiratory compromise.Hypersensitivity reactions, including anaphylaxis to esmolol or any of the inactive ingredients of the product (cross-sensitivity between beta blockers is possible).

 

 

 

 

Hypotension can occur at any dose but is dose-related. Patients with hemodynamic compromise or on interacting medications are at particular risk. Severe reactions may include loss of consciousness, cardiac arrest, and death. For control of ventricular heart rate, maintenance doses greater than 200 mcg per kg per min are not recommended. Monitor patients closely, especially if pretreatment blood pressure is low. In case of an unacceptable drop in blood pressure, reduce or stop Brevibloc injection. Decrease of dose or termination of infusion reverses hypotension, usually within 30 minutes.

Bradycardia, including sinus pause, heart block, severe bradycardia, and cardiac arrest have occurred with the use of Brevibloc injection. Patients with first-degree atrioventricular block, sinus node dysfunction, or conduction disorders may be at increased risk. Monitor heart rate and rhythm in patients receiving Brevibloc [see Contraindications (4)].

If severe bradycardia develops, reduce or stop Brevibloc.

Beta blockers, like Brevibloc injection, can cause depression of myocardial contractility and may precipitate heart failure and cardiogenic shock. At the first sign or symptom of impending cardiac failure, stop Brevibloc and start supportive therapy [see Overdosage (10)].

Monitor vital signs closely and titrate Brevibloc slowly in the treatment of patients whose blood pressure is primarily driven by vasoconstriction associated with hypothermia.

Patients with reactive airways disease should, in general, not receive beta blockers. Because of its relative beta1 selectivity and titratability, titrate Brevibloc to the lowest possible effective dose. In the event of bronchospasm, stop the infusion immediately; a beta2 stimulating agent may be administered with appropriate monitoring of ventricular rates.

In patients with hypoglycemia, or diabetic patients (especially those with labile diabetes) who are receiving insulin or other hypoglycemic agents, beta blockers may mask tachycardia occurring with hypoglycemia, but other manifestations such as dizziness and sweating may not be masked.

Concomitant use of beta blockers and antidiabetic agents can enhance the effect of antidiabetic agents (blood glucose-lowering).

Infusion site reactions have occurred with the use of Brevibloc injection. They include irritation, inflammation, and severe reactions (thrombophlebitis, necrosis, and blistering), in particular when associated with extravasation [see Adverse Reactions (6)]. Avoid infusions into small veins or through a butterfly catheter.

If a local infusion site reaction develops, use an alternative infusion site and avoid extravasation.

Beta blockers may exacerbate anginal attacks in patients with Prinzmetal's angina because of unopposed alpha receptor-mediated coronary artery vasoconstriction. Do not use nonselective beta blockers.

If Brevibloc is used in the setting of pheochromocytoma, give it in combination with an alpha-blocker, and only after the alpha-blocker has been initiated. Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure from the attenuation of beta-mediated vasodilation in skeletal muscle.

In hypovolemic patients, Brevibloc injection can attenuate reflex tachycardia and increase the risk of hypotension.

In patients with peripheral circulatory disorders (including Raynaud's disease or syndrome, and peripheral occlusive vascular disease), Brevibloc may aggravate peripheral circulatory disorders.

Severe exacerbations of angina, myocardial infarction, and ventricular arrhythmias have been reported in patients with coronary artery disease upon abrupt discontinuation of beta blocker therapy. Observe patients for signs of myocardial ischemia when discontinuing Brevibloc.

Heart rate increases moderately above pretreatment levels 30 minutes after Brevibloc discontinuation.

Beta blockers, including Brevibloc, have been associated with increases in serum potassium levels and hyperkalemia. The risk is increased in patients with risk factors such as renal impairment. Intravenous administration of beta blockers has been reported to cause potentially life-threatening hyperkalemia in hemodialysis patients. Monitor serum electrolytes during therapy with Brevibloc.

Beta blockers, including Brevibloc, have been reported to cause hyperkalemic renal tubular acidosis. Acidosis in general may be associated with reduced cardiac contractility.

Beta-adrenergic blockade may mask certain chemical signs (e.g., tachycardia) of hyperthyroidism. Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, monitor patients for signs of thyrotoxicosis when withdrawing beta blocking therapy.

When using beta blockers, patients at risk of anaphylactic reactions may be more reactive to allergen exposure (accidental, diagnostic, or therapeutic).

Patients using beta blockers may be unresponsive to the usual doses of epinephrine used to treat anaphylactic or anaphylactoid reactions [see Drug Interactions (7)].

 

 

 

 

 

 

 

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The following adverse reaction rates are based on use of Brevibloc (Esmolol Hydrochloride) in clinical trials involving 369 patients with supraventricular tachycardia and over 600 intraoperative and postoperative patients enrolled in clinical trials. Most adverse effects observed in controlled clinical trial settings have been mild and transient. The most important and common adverse effect has been hypotension [see Warnings and Precautions (5.1)]. Deaths have been reported in post-marketing experience occurring during complex clinical states where Brevibloc was presumably being used to control ventricular rate [see Warnings and Precautions (5.5)].

Clinical Trial Adverse Reactions (Frequency <3%)

Psychiatric Disorders

Confusional state and agitation (~2%)

Anxiety, depression and abnormal thinking (<1%)

Nervous System Disorders

Headache (~ 2%)

Paresthesia, syncope, speech disorder, and lightheadedness (<1%)

Convulsions (<1%), with one death

Vascular Disorders

Peripheral ischemia (~1%)

Pallor and flushing (<1%)

Gastrointestinal Disorders

Vomiting (~1%)

Dyspepsia, constipation, dry mouth, and abdominal discomfort (<1%)

Renal and Urinary Disorders

Urinary retention (<1%)

In addition to the adverse reactions reported in clinical trials, the following adverse reactions have been reported in the post-marketing experience. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or to establish a causal relationship to drug exposure.

Cardiac Disorders

Cardiac arrest, Coronary arteriospasm

Skin and Subcutaneous Tissue Disorders

Angioedema, Urticaria, Psoriasis

Concomitant use of Brevibloc injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate Brevibloc's effects on blood pressure, contractility, and impulse propagation. Severe interactions with such drugs can result in, for example, severe hypotension, cardiac failure, severe bradycardia, sinus pause, sinoatrial block, atrioventricular block, and/or cardiac arrest. In addition, with some drugs, beta blockade may precipitate increased withdrawal effects. (See clonidine, guanfacine, and monoxide below.) Brevibloc should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to:

Digitalis glycosides:  Concomitant administration of digoxin and Brevibloc leads to an approximate 10% to 20% increase of digoxin blood levels at some time points. Digoxin does not affect Brevibloc pharmacokinetics. Both digoxin and beta blockers slow atrioventricular conduction and decrease the heart rate. Concomitant use increases the risk of bradycardia.Anticholinesterases:  Brevibloc prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium.Antihypertensive agents clonidine, guanfacine, or moxonidine:  Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. If, during concomitant use of a beta blocker, antihypertensive therapy needs to be interrupted or discontinued, discontinue the beta blocker first, and the discontinuation should be gradual.Calcium channel antagonists:  In patients with depressed myocardial function, use of Brevibloc with cardiodepressant calcium channel antagonists (e.g., verapamil) can lead to fatal cardiac arrests.Sympathomimetic drugs:  Sympathomimetic drugs having beta-adrenergic agonist activity will counteract effects of Brevibloc.Vasoconstrictive and positive inotropic agents:  Because of the risk of reducing cardiac contractility in presence of high systemic vascular resistance, do not use Brevibloc to control tachycardia in patients receiving drugs that are vasoconstrictive and have positive inotropic effects, such as epinephrine, norepinephrine, and dopamine.

Pregnancy Category C. Esmolol hydrochloride has been shown to produce increased fetal resorptions with minimal maternal toxicity in rabbits when given in doses approximately 8 times the maximum human maintenance dose (300 mcg/kg/min). There are no adequate and well-controlled studies in pregnant women. Brevibloc injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Teratogenicity studies in rats at intravenous dosages of esmolol hydrochloride up to 3000 mcg/kg/min (10 times the maximum human maintenance dosage) for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while a dosage of 10,000 mcg/kg/min produced maternal toxicity and lethality. In rabbits, intravenous dosages up to 1000 mcg/kg/min for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while 2500 mcg/kg/min produced minimal maternal toxicity and increased fetal resorptions.

Although there are no adequate and well-controlled studies in pregnant women, use of esmolol in the last trimester of pregnancy or during labor or delivery has been reported to cause fetal bradycardia, which continued after termination of drug infusion. Brevibloc injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

 

 

 

 

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Brevibloc, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

The safety and effectiveness of Brevibloc in pediatric patients have not been established.

Clinical studies of Brevibloc injection did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should usually start at the low end of the dosing range, reflecting greater frequency of decreased renal or cardiac function and of concomitant disease or other drug therapy.

No special precautions are necessary in patients with hepatic impairment because Brevibloc is metabolized by red-blood cell esterases [see Clinical Pharmacology (12)].

No dosage adjustment is required for esmolol in patients with renal impairment receiving a maintenance infusion of esmolol 150 mcg/kg for 4 hours. There is no information on the tolerability of maintenance infusions of esmolol using rates in excess of 150 mcg/kg or maintained longer than 4 hours [see Clinical Pharmacology (12)].

Overdoses of Brevibloc (Esmolol Hydrochloride) can cause cardiac and central nervous system effects. These effects may precipitate severe signs, symptoms, sequelae, and complications (for example, severe cardiac and respiratory failure, including shock and coma), and may be fatal. Continuous monitoring of the patient is required.

Cardiac effects include bradycardia, atrioventricular block (1st-, 2nd, 3rd degree), junctional rhythms, intraventricular conduction delays, decreased cardiac contractility, hypotension, cardiac failure (including cardiogenic shock), cardiac arrest/asystole, and pulseless electrical activity.Central nervous system effects include respiratory depression, seizures, sleep and mood disturbances, fatigue, lethargy, and coma.In addition, bronchospasm, mesenteric ischemia, peripheral cyanosis, hyperkalemia, and hypoglycemia (especially in children) may occur.

Because of its approximately 9-minute elimination half-life, the first step in the management of toxicity should be to discontinue the Brevibloc infusion. Then, based on the observed clinical effects, consider the following general measures.

Bradycardia

Consider intravenous administration of atropine or another anticholinergic drug or cardiac pacing.

Cardiac Failure

Consider intravenous administration of a diuretic or digitalis glycoside. In shock resulting from inadequate cardiac contractility, consider intravenous administration of dopamine, dobutamine, isoproterenol, or inamrinone. Glucagon has been reported to be useful.

Symptomatic hypotension

Consider intravenous administration of fluids or vasopressor agents such as dopamine or norepinephrine.

Bronchospasm

Consider intravenous administration of a beta2 stimulating agent or a theophylline derivative.

Massive accidental overdoses of Brevibloc have resulted from dilution errors. Use of Brevibloc PREMIXED Injection and Brevibloc DOUBLE STRENGTH PREMIXED Injection may reduce the potential for dilution errors. Some of these overdoses have been fatal while others resulted in permanent disability. Bolus doses in the range of 625 mg to 2.5 g (12.5-50 mg/kg) have been fatal. Patients have recovered completely from overdoses as high as 1.75 g given over one minute or doses of 7.5 g given over one hour for cardiovascular surgery. The patients who survived appear to be those whose circulation could be supported until the effects of Brevibloc resolved.

 

 

 

Brevibloc (Esmolol Hydrochloride) is a beta adrenergic receptor blocker with a very short duration of action (elimination half-life is approximately 9 minutes). Esmolol hydrochloride is:

(±)-Methyl p-[2-hydroxy-3-(isopropylamino) propoxy] hydrocinnamate hydrochloride and has the following structure:

Esmolol hydrochloride has the empirical formula C16H26NO4Cl and a molecular weight of 331.8. It has one asymmetric center and exists as an enantiomeric pair.Esmolol hydrochloride is a white to off-white crystalline powder. It is a relatively hydrophilic compound which is very soluble in water and freely soluble in alcohol. Its partition coefficient (octanol/water) at pH 7.0 is 0.42 compared to 17.0 for propranolol.

All Brevibloc presentations are clear, colorless to light yellow, sterile, nonpyrogenic, iso-osmotic solutions of esmolol hydrochloride in sodium chloride. The formulations for Brevibloc PREMIXED Injection, Brevibloc DOUBLE STRENGTH PREMIXED Injection, and Brevibloc Injection are described in the table below:

The calculated osmolarity of Brevibloc PREMIXED Injection and Brevibloc DOUBLE STRENGTH PREMIXED Injection is 312 mOsmol/L. The 250 mL and 100 mL bags are non-latex, non-PVC INTRAVIA bags with dual PVC ports. The INTRAVIA bags are manufactured from a specially designed multilayer plastic (PL 2408). Solutions in contact with the plastic container leach out certain chemical compounds from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials.

Brevibloc (Esmolol Hydrochloride) is a beta1-selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Its elimination half-life after intravenous infusion is approximately 9 minutes. Brevibloc inhibits the beta1 receptors located chiefly in cardiac muscle, but this preferential effect is not absolute and at higher doses it begins to inhibit beta2 receptors located chiefly in the bronchial and vascular musculature.

Clinical pharmacology studies in normal volunteers have confirmed the beta blocking activity of Brevibloc, showing reduction in heart rate at rest and during exercise, and attenuation of isoprotenerol-induced increases in heart rate. Blood levels of Brevibloc have been shown to correlate with extent of beta blockade. After termination of infusion, substantial recovery from beta blockade is observed in 10-20 minutes. The acid metabolite of esmolol exhibits negligible pharmacological activity.

In human electrophysiology studies, Brevibloc produced effects typical of a beta blocker:  a decrease in the heart rate, increase in sinus cycle length, prolongation of the sinus node recovery time, prolongation of the AH interval during normal sinus rhythm and during atrial pacing, and an increase in antegrade Wenckebach cycle length.

In patients undergoing radionuclide angiography, Brevibloc, at dosages of 200 mcg/kg/min, produced reductions in heart rate, systolic blood pressure, rate pressure product, left and right ventricular ejection fraction and cardiac index at rest, which were similar in magnitude to those produced by intravenous propranolol (4 mg). During exercise, Brevibloc produced reductions in heart rate, rate pressure product and cardiac index which were also similar to those produced by propranolol, but Brevibloc produced a significantly larger fall in systolic blood pressure. In patients undergoing cardiac catheterization, the maximum therapeutic dose of 300 mcg/kg/min of Brevibloc produced similar effects and, in addition, there were small, clinically insignificant increases in the left ventricular end diastolic pressure and pulmonary capillary wedge pressure. At 30 minutes after the discontinuation of Brevibloc infusion, all of the hemodynamic parameters had returned to pretreatment levels.

The relative cardioselectivity of Brevibloc was demonstrated in 10 mildly asthmatic patients. Infusions of Brevibloc 100, 200 and 300 mcg/kg/min produced no significant increases in specific airway resistance compared to placebo. At 300 mcg/kg/min, Brevibloc produced slightly enhanced bronchomotor sensitivity to dry air stimulus. These effects were not clinically significant, and Brevibloc was well tolerated by all patients. Six of the patients also received intravenous propranolol, and at a dosage of 1 mg, two experienced significant, symptomatic bronchospasm requiring bronchodilator treatment. One other propranolol-treated patient also experienced dry air-induced bronchospasm. No adverse pulmonary effects were observed in patients with COPD who received therapeutic dosages of Brevibloc for treatment of supraventricular tachycardia (51 patients) or in perioperative settings (32 patients).

Esmolol is rapidly metabolized by hydrolysis of the ester linkage, chiefly by the esterases in the cytosol of red blood cells and not by plasma cholinesterases or red cell membrane acetylcholinesterase. Total body clearance in man was found to be about 20 L/kg/hr, which is greater than cardiac output; thus the metabolism of esmolol is not limited by the rate of blood flow to metabolizing tissues such as the liver or affected by hepatic or renal blood flow. Esmolol has a rapid distribution half-life of about 2 minutes and an elimination half-life of about 9 minutes.

 

 

 

 

 

 

 

Using an appropriate loading dose, steady-state blood levels of Brevibloc for dosages from 50-300 mcg/kg/min are obtained within five minutes. Steady-state is reached in about 30 minutes without the loading dose. Steady-state blood levels of esmolol increase linearly over this dosage range and elimination kinetics are dose-independent over this range. Steady-state blood levels are maintained during infusion but decrease rapidly after termination of the infusion. Because of its short half-life, blood levels of esmolol can be rapidly altered by increasing or decreasing the infusion rate and rapidly eliminated by discontinuing the infusion.

Consistent with the high rate of blood-based metabolism of esmolol, less than 2% of the drug is excreted unchanged in the urine. Within 24 hours of the end of infusion, the acid metabolite of esmolol in urine accounts for approximately 73-88% of the dosage.

Metabolism of esmolol results in the formation of the corresponding free acid and methanol. The acid metabolite has been shown in animals to have negligible activity and in normal volunteers its blood levels do not correspond to the level of beta blockade. The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent tot he glomerular filtration rate. After a 4 hour maintenance infusion of 150 mcg/kg, the plasma concentrations of esmolol are similar in subjects with normal renal function and in patients with ESRD on dialysis. The half-life of the acid metabolite of Brevibloc, which is primarily excreted unchanged by the kidney, is increased about 12-fold to 48 hours in patients with ESRD. The peak concentrations of the acid metabolite are doubled in ESRD.

Methanol blood levels, monitored in subjects receiving Brevibloc for up to 6 hours at 300 mcg/kg/min and 24 hours at 150 mcg/kg/min, approximated endogenous levels and were less than 2% of levels usually associated with methanol toxicity.

Brevibloc has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound.

Because of its short term usage no carcinogenicity, mutagenicity, or reproductive performance studies have been conducted with esmolol.

Supraventricular Tachycardia

In two multicenter, randomized, double-blind, controlled comparisons of Brevibloc injection with placebo and propranolol, maintenance doses of 50 to 300 mcg/kg/min of Brevibloc were found to be more effective than placebo and about as effective as propranolol, 3-6 mg given by bolus injections, in the treatment of supraventricular tachycardia, principally atrial fibrillation and atrial flutter. The majority of these patients developed their arrhythmias postoperatively. After 60-70% of the patients treated with Brevibloc developed either a 20% reduction in heart rate, a decrease in heart rate to less than 100 bpm, or, rarely, conversion to normal sinus rhythm and about 95% of these patients did so at a dosage of 200 mcg/kg/min or less. The average effective dosage of Brevibloc was approximately 100 mcg/kg/min in the two studies. Other multicenter baseline-controlled studies gave similar results. In the comparison with propranolol, about 50% of patients in both the Brevibloc and propranolol groups were on concomitant digoxin. Response rates were slightly higher with both beta blockers in the digoxin-treated patients.

In all studies significant decreases of blood pressure occurred in 20-50% of patients, identified either as adverse reaction reports by investigators, or by observation of systolic pressure less than 90 mmHg or diastolic pressure less than 50 mmHg. The hypotension was symptomatic (mainly hyperhidrosis or dizziness) in about 12% of patients, and therapy was discontinued in about 11% of patients, about half of whom were symptomatic. Hypotension was more common with Brevibloc (53%) than with propranolol (17%). The hypotension was rapidly reversible with decreased infusion rate or after discontinuation of therapy with Brevibloc. For both Brevibloc and propranolol, hypotension was reported less frequently in patients receiving concomitant digoxin.

Brevibloc PREMIXED Injection

NDC 10019-055-61, 2500 mg / 250 mL (10 mg/mL) Ready-to-use INTRAVIA Bags

Brevibloc DOUBLE STRENGTH PREMIXED Injection

NDC 10019-075-87, 2000 mg / 100 mL (20 mg/mL) Ready-to-use INTRAVIA Bags

Brevibloc Injection

NDC 10019-115-01, 100 mg / 10 mL (10 mg/mL) Ready-to-use Vials, Package of 25

Store at 25°C (77°F). Excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Protect from freezing. Avoid excessive heat.

 

 

 

Each bag contains no preservative. Once drug has been withdrawn from ready-to-use bag, the bag should be used within 24 hours, with any unused portion discarded.

Do not use plastic containers in series connections. Such use could result in an embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.

Do not remove unit from overwrap until ready to use. Do not use if overwrap has been previously opened or damaged. The overwrap is a moisture barrier. The inner bag maintains sterility of the solution. Tear overwrap at notch and remove premixed bag. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.

Check for minute leaks by squeezing the inner bag firmly. If leaks are found, discard solution, as sterility may be impaired. Do not use unless the solution is clear (colorless to light yellow) and the seal is intact.

Preparation for intravenous administration:

Use aseptic techniqueSuspend premixed bag from eyelet support.Remove plastic protector from delivery port at bottom of bag.Attach administration set.Refer to complete directions accompanying set.

Physicians should inform patients of the risks associated with Brevibloc injection:

The most common adverse reactions are symptomatic hypotension (hyperhidrosis, dizziness) and asymptomatic hypotension.

Baxter

Manufactured for

Baxter Healthcare Corporation

Deerfield,IL60015USA

Baxter, Brevibloc, Brevibloc Premixed and Intravia are trademarks of Baxter International Inc.

07-19-73-099

462-409-05

Brevibloc Brevibloc injection

Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:52584-115(NDC:10019-115) Route of Administration INTRAVENOUS DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Esmolol Hydrochloride (Esmolol) Esmolol Hydrochloride 10 mg  in 1 mL

Packaging # Item Code Package Description   1 NDC:52584-115-39 1 VIAL, SINGLE-DOSE in 1 BAG   1   10 mL in 1 VIAL, SINGLE-DOSE

Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA019386 07/01/2010

Labeler - General Injectables & Vaccines (108250663)

Revised: 08/2017

 

General Injectables & Vaccines